Perfluoroalkyl chemicals and elevated serum uric acid in US adults by Shankar, Anoop et al.
© 2011 Shankar et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
Clinical Epidemiology 2011:3 251–258
Clinical Epidemiology
Perfluoroalkyl chemicals and elevated  




Department of Community Medicine, 
West Virginia University School of 
Medicine, Morgantown, WV, USA
Correspondence: Anoop Shankar 
Department of Community Medicine, 
West Virginia University School of 
Medicine, 1 Medical Center Drive,  
PO Box 9190, Morgantown,  
WV 26506, USA 
Tel +1 304 293 0199 
Fax +1 304 293 6685 
Email ashankar@hsc.wvu.edu
Background: Perfluoroalkyl chemicals, including perfluorooctanoic acid and perfluorooctane 
sulfonate, are man-made chemicals that have been detected in the blood of over 98% of the 
US population. Serum uric acid is a novel biomarker, even mild elevations of which has been 
implicated in the development of hypertension, diabetes mellitus, cardiovascular disease, and 
chronic kidney disease. We examined the relationship of serum perfluoroalkyl chemicals, 
including perfluorooctanoic acid and perfluorooctane sulfonate, and elevated uric acid levels 
in a representative sample of US adults.
Methods: We examined 3883 participants from the 1999–2000 and 2003–2006 National Health 
and Nutritional Examination Surveys, a representative, multiethnic population-based survey 
of noninstitutionalized US adults. Serum perfluorooctanoic acid and perfluorooctane sulfonate 
were analyzed as quartiles. The main outcome was hyperuricemia.
Results: We found that serum levels of perfluoroalkyl chemicals, including perfluorooctanoic 
acid and perfluorooctane sulfonate, were positively associated with hyperuricemia. This 
association appeared to be independent of confounders such as age, gender, race-ethnicity, 
body mass index, diabetes, hypertension, and serum cholesterol. Compared with subjects in 
quartile 1 (referent), the multivariate odds ratio for hyperuricemia among subjects in quartile 4 
was 1.97 (95% confidence interval 1.44–2.70, P , 0.0001) for perfluorooctanoic acid and 1.48% 
(95% confidence interval 0.99–2.22, P = 0.0433) for perfluorooctane sulfonate. This observed 
association persisted in subgroup analysis by gender and body mass index.
Conclusion: Our results demonstrate that elevated levels of perfluoroalkyl chemicals are 
associated with hyperuricemia even at low perfluoroalkyl chemical exposure levels as seen in 
the US general population.
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Introduction
There is concern regarding human exposure to perfluoroalkyl chemicals, including 
perfluorooctanoic acid and perfluorooctane sulfonate, because these chemicals are 
persistent in the environment, bioaccumulated, biomagnified along food chains, and 
have been shown to cause developmental and other adverse health effects in laboratory 
animals.1,2 Perfluoroalkyl chemicals have been widely used in the manufacture of 
industrial and consumer products such as surfactants, lubricants, polishes, paper and 
textile coatings, food packaging, and fire-retarding foams.2 Perfluoroalkyl chemicals 
have been detected in the blood of more than 98% of the US population.3
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Uric acid is a byproduct of purine metabolism which 
has both oxidant as well as antioxidant properties. Several 
studies have shown that higher serum uric acid levels are 
associated with markers of inflammation,4 insulin resistance,5 
and elevated lipid levels.6 Studies have also reported an 
association between higher serum uric acid levels and risk of 
developing hypertension,7 diabetes mellitus,8 chronic kidney 
disease,9 and cardiovascular disease.10 High levels of serum 
uric acid is also considered to be the underlying metabolic 
derailment in gout.11
Sakr et al12,13 and Costa et al14 in two separate cohorts of 
occupationally exposed workers reported that perfluorooc-
tanoic acid levels are cross-sectionally associated with ele-
vated uric acid. Recently, Steenland et al15 reported modest 
positive associations between both serum perfluorooctanoic 
acid and perfluorooctane sulfonate levels and elevated uric 
acid in the C8 Health Study, a community-based study of 
residents in six water districts in Ohio and West Virginia 
who were exposed to very high levels of perfluorooctanoic 
acid following contamination from a chemical plant. 
However, perfluorooctanoic acid exposure levels in the US 
general population are much lower than those reported in 
these studies which examined high-  exposure populations. 
In this context, a recent report based on a community-
based sample of subjects exposed to perfluorooctanoic 
acid emissions from an industrial facility reported a con-
centration-dependent clearance for perfluorooctanoic acid, 
with half-lives of 2.9 years at higher exposure levels and 
8.5 years for lower exposure levels.16 Therefore, it is also 
important to study perfluorooctanoic acid exposure at 
lower serum levels because at such concentrations these 
chemicals may potentially persist in the body for longer. 
Therefore, we examined if there was a positive association 
between serum perfluoroalkyl chemicals and uric acid in 
the National Health and Nutritional Examination Survey 
(NHANES), a representative, multiethnic sample of the US 
general population.
Materials and methods
The current study is based on six years of combined data 
from the 1999–2000, 2003–2004, and 2005–2006 NHANES. 
Detailed description of the NHANES study design and 
methods are available elsewhere.17 In brief, the NHANES 
survey included a stratified, multistage probability sample 
representative of the civilian noninstitutionalized US 
population. Selection was based on counties, blocks, house-
holds, and individuals within households, and included the 
oversampling of low-income persons, persons 60+ years, 
African Americans, and Mexican Americans in order 
to provide stable estimates of these groups. The survey 
also includes biomonitoring for different environmental 
chemicals, including perfluoroalkyl chemicals, in a random 
one third subsample of participants by the National Center 
for Environmental Health. Subjects were required to sign a 
consent form before their participation, and approval was 
obtained from the Human Subjects Committee at the US 
Department of Health and Human Service.
The current study sample consisted of 3974 participants 
aged $20  years  who  had  perfluoroalkyl  chemical 
measurements available. We excluded subjects with missing 
data (n = 91) on uric acid and covariates included in the 
multivariable model, including education level, body mass 
index, or cholesterol levels. This resulted in 3883 participants 
(51.7% women).
Exposure measurements
Age, gender, race/ethnicity, smoking status, alcohol intake 
(g/day), level of education, history of diabetes, oral hypo-
glycemic intake, insulin administration, and antihypertensive 
medication use were assessed using a questionnaire. 
Individuals who had not smoked $100 cigarettes in their 
lifetimes were considered never smokers; those who had 
smoked $100 cigarettes in their lifetimes were considered 
former smokers if they answered negatively to the question 
“Do you smoke now?” and current smokers if they answered 
affirmatively. Body mass index was calculated as weight 
in kilograms divided by height in meters squared. Heavy 
drinking was defined as consumption of more than two 
drinks/day for the question on an average alcohol intake over 
the past 12 months.
Rigorous procedures with quality control checks 
were used in blood collection, and details about these 
procedures are provided in the NHANES Laboratory/
Medical Technologists Procedures Manual.18 Perfluoroalkyl 
chemicals were measured in serum by the National Center 
for Environmental Health using automated solid-phase 
extraction coupled to isotope dilution high-performance 
liquid chromatography-tandem mass spectrometry; details 
of laboratory methods are available elsewhere.3 Our study 
examined the perfluoroalkyl chemicals, perfluorooctanoic 
acid and perfluorooctane sulfonate, that were detected 
in greater than 98% of people. Values below the limit of 
detection were reported by NHANES as the limit of detection 
divided by the square root of 2.
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Serum total cholesterol was measured enzymatically. 
Seated systolic and diastolic blood pressures were measured 
using a mercury sphygmomanometer according to the 
American Heart Association and Seventh Joint National 
Committee (JNC7) recommendations.19 Up to three measure-
ments were averaged for systolic and diastolic pressures. 
Patients were considered hypertensive if they reported 
current blood pressure-reducing medication use and/or had 
systolic blood pressures $140 mmHg and/or diastolic blood 
  pressures $90 mmHg.
Outcome of interest
The main outcome of interest was serum uric acid level or the 
presence of hyperuricemia. Uric acid was measured using 
the Beckman Synchron LX20 system. Details of laboratory 
measurement are available online.20 In brief, uric acid is 
oxidized by uricase to produce allatoin and hydrogen peroxide. 
The hydrogen peroxide reacts with 4-aminoantipyrine and 
3,5-dichloro-2-hydroxybenzene sulfonate in a reaction 
catalyzed by peroxidase to produce a colored product. The 
Beckman Synchron LX20 system monitors the change in 
absorbance at 520 nm at a fixed time interval. The change in 
absorbance is directly proportional to the concentration of uric 
acid in the sample. Coulston Foundation at Alamogordo, New 
Mexico, performed testing in 1999–2000 and Collaborative 
Laboratory Services at Ottumwa, Iowa, performed testing in 
2003–2004. Hyperuricemia was defined as serum uric acid 
levels .6.8 mg/dL in men and .6.0 mg/dL in women.11
Statistical analysis
Serum perfluoroalkyl chemicals, including perfluorooctanoic 
acid and perfluorooctane sulfonate, were analyzed both as a 
continuous as well as a categorical variable. For analysis as a 
continuous variable, perfluoroalkyl chemical values were log-
transformed (base 2) as a result of their skewed distribution. 
We also categorized serum perfluoroalkyl chemicals into 
quartiles. We ran linear regression models with serum 
perfluoroalkyl chemical quartiles as the independent 
variable to examine the mean change in serum uric acid with 
increasing categories of perfluoroalkyl chemical, taking the 
lowest perfluoroalkyl chemical quartile as the referent. We 
ran three nested models, ie, the unadjusted model, the age 
and gender-adjusted model, and the multivariable-adjusted 
model, additionally adjusting for race-ethnicity (non-Hispanic 
whites, non-Hispanic blacks, Mexican Americans, others), 
education categories (,high school, high school, .high 
school), smoking (never, former, current), alcohol intake 
(heavy drinker), body mass index (kg/m2), hypertension 
(absent, present), diabetes (absent, present), and serum total 
cholesterol (mg/dL). Subsequently, we ran multivariable 
logistic regression models to calculate the odds ratio ([OR], 
95% confidence interval [CI]) of hyperuricemia for each 
higher perfluoroalkyl chemical level by taking the lowest 
category as the referent. Trends in the OR of hyperuricemia 
across increasing serum perfluoroalkyl chemical levels were 
determined by modeling perfluoroalkyl chemical categories 
as an ordinal variable. As recommended by the National 
Center for Health Statistics,21 sample weights that account 
for the unequal probabilities of selection, oversampling, 
and nonresponse in the NHANES survey were applied for 
all analyses. Analyses were conducted using SUDAAN 
(version 8.0, Research Triangle Institute, Research Triangle 
Park, NC) and SAS (version 9.2, SAS Institute, Cary, NC) 
software. Standard errors were estimated using the Taylor 
series linearization method.
Results
Table 1 presents the characteristics of the population. 
Overall, this was a middle-aged representative sample 
of the US population. It comprised 51.7% women, 
Table 1 Characteristics of study population
Characteristics Percentages or mean values ± SE
Unweighted sample size 3883
Age, years 46.4 ± 0.5
Women, % 51.7
race-ethnicity, %
  non-hispanic whites 73.5
  non-hispanic blacks 10.7
  Mexican Americans 7.8
  Others 8.0
Education categories, %
  Below high school 18.5
  high school 27.1
  Above high school 54.4
Smoking, %
  never smoker 49.9
  Former smoker 26.0
  Current smoker 24.1
Alcohol intake, %
  heavy drinker 24.3
Body mass index, kg/m2 28.5 ± 0.2
Total cholesterol, mg/dL 200.7 ± 0.9
Diabetes mellitus, % 10.2
hypertension, % 31.2
Serum uric acid, mg/dL 5.4 ± 0.04
hyperuricemia, % 19.2
Abbreviation: SE, standard error of the mean.
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73.5% non-Hispanic whites, 10.7% non-Hispanic blacks, 
and 7.8% Mexican Americans. The mean serum uric acid 
level was 5.4 mg/dL, and 19.2% of the population had 
hyperuricemia.
Table 2 presents the association between increasing 
serum perfluorooctanoic acid, perfluorooctane sulfonate, 
and uric acid in the whole study sample. We observed a 
positive association between increasing quartiles of serum 
perfluorooctanoic acid and perfluorooctane sulfonate and a 
change in uric acid levels in the unadjusted, age-adjusted, 
and gender-adjusted models, as well as the multivariable-
adjusted models. Models evaluating trend in this association 
were also statistically significant.
Tables 3 and 4 present the association between increas-
ing serum perfluorooctanoic acid and perfluorooctane sul-
fonate and serum uric acid stratified by gender and body 
mass index categories, respectively. Similar to the results 
in Table 2, we observed a positive association between 
increasing quartiles of serum perfluorooctanoic acid and 
perfluorooctane sulfonate and change in uric acid levels. 
Models evaluating trend in this association were also 
statistically significant.
Table 5 presents the association between increasing 
serum perfluorooctanoic acid and perfluorooctane   sulfonate 
and the presence of hyperuricemia. We observed a 
positive association between increasing quartiles of serum 
perfluorooctanoic acid and perfluorooctane sulfonate and the 
odds of hyperuricemia in the unadjusted, age-adjusted, and 
gender-adjusted models, as well as the multivariable-adjusted 
models. Models evaluating trend in this association were also 
statistically significant.
Discussion
In a representative sample of US adults, we found that 
serum perfluoroalkyl chemical levels were positively asso-
ciated with elevated uric acid. The association was found 
to be independent of age, gender, race-ethnicity, education, 
smoking, alcohol intake, body mass index, hypertension, 
diabetes, and serum total cholesterol. We found that both 
perfluorooctanoic acid and perfluorooctane sulfonate levels 
were associated with elevated uric acid in separate   analyses. 
Our results contribute to the existing literature, which 
had demonstrated an association between perfluoroalkyl 
chemicals and uric acid in groups who were exposed to 
very high perfluoroalkyl chemical levels, by suggesting 
that perfluoroalkyl chemical levels are positively related 
to uric acid, even at low exposure levels as seen in the US 
general population.
Hyperuricemia is the underlying mechanism in gout, 
a clinical condition where high levels of serum uric acid result 
in deposition of monosodium urate crystals in the synovial 
fluid of joints and in the interstitial space and tubules of renal 
cells resulting, respectively, in arthritis and kidney disease.11 
Furthermore, emerging animal and human studies suggest 
Table 2 Association between serum PFOA level and uric acid levels
Plasma PFC level* Sample size Unadjusted mean  
change in uric acid,  
mg/dL (95% CI)
Age, gender-adjusted  
mean change in uric acid,  
mg/dL (95% CI)
Multivariate-adjusted   
mean change in uric  
acid, mg/dL (95% CI)‡
PFOA*
  Quartile 1 984 1 (referent) 1 (referent) 1 (referent)
  Quartile 2 931 0.20 (0.05, 0.34) 0.15 (0.03, 0.27) 0.14 (0.04, 0.25)
  Quartile 3 1003 0.40 (0.23, 0.56) 0.37 (0.23, 0.51) 0.37 (0.25, 0.49)
  Quartile 4 965 0.56 (0.43, 0.68) 0.48 (0.35, 0.60) 0.44 (0.32, 0.56)
 P  trend ,0.0001 ,0.0001 ,0.0001
Log-transformed PFOA 0.45 (0.37, 0.53) 0.25 (0.17, 0.32) 0.22 (0.15, 0.30)
PFOS†
  Quartile 1 967 1 (referent) 1 (referent) 1 (referent)
  Quartile 2 969 0.12 (-0.07, 0.30) 0.16 (-0.01, 0.32) 0.18 (0.05, 0.31)
  Quartile 3 978 0.28 (0.10, 0.45) 0.24 (0.05, 0.43) 0.22 (0.04, 0.40)
  Quartile 4 969 0.29 (0.11, 0.46) 0.26 (0.09, 0.44) 0.27 (0.13, 0.41)
 P  trend 0.0006 0.0051 0.0018
Log-transformed PFOS 0.40 (0.31, 0.50) 0.16 (0.05, 0.26) 0.14 (0.05, 0.23)
Notes: *Plasma PFOA quartiles: quartile 1 (,2.4 ppb), quartile 2 (2.4–3.4 ppb), quartile 3 (3.5–5.1 ppb), quartile 4 (.5.1 ppb); in men: quartile 1 (,3.2 ppb), quartile 2 
(3.2–4.5 ppb), quartile 3 (4.6–6.4 ppb), quartile 4 (.6.4 ppb); †plasma PFOS quartiles: quartile 1 (,11.2 ppb), quartile 2 (11.2–17.8 ppb), quartile 3 (17.9–27.9 ppb), quartile 4 
(.27.9 ppb); in men: quartile 1 (,17.5 ppb), quartile 2 (17.5–24.7 ppb), quartile 3 (24.8–35.6 ppb), quartile 4 (.35.6 ppb); ‡adjusted for age (years), gender (men, women), 
race-ethnicity (non-hispanic whites, non-hispanic blacks, Mexican Americans, others), education categories (,high school, high school, .high school), smoking (never, 
former, current), alcohol intake (heavy drinker), body mass index (kg/m2), hypertension (absent, present), diabetes (absent, present), and serum total cholesterol (mg/dL). 
Abbreviations: CI, confidence interval; PFOA, perfluorooctanoic acid; PFOS, perfluorooctane sulfonate.
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that even mild elevations in serum uric acid may be associated 
with increased risk of developing hypertension, chronic 
kidney disease, and cardiovascular outcomes.22 Therefore, 
identifying environmental factors associated with elevated 
levels of serum uric acid may have clinical and public health 
significance.
There is limited previous research available on the 
effect of perfluoroalkyl chemicals on uric acid, with only 
two occupational studies and one community-based study 
examining this hypothesis. In a cross-sectional study of 
1025 active workers exposed to perfluorooctanoic acid from 
a chemical plant based in the US, Sakr et al12,13 reported a 
modest positive association between serum perfluorooc-
tanoic acid levels and uric acid. In a more recent study of 
53 male workers at a perfluorooctanoic acid production 
plant from Italy, Costa et al14 reported a similar positive 
association between serum perfluorooctanoic acid levels 
and uric acid. In a large, community-based, cross-sectional 
study of perfluorooctanoic acid and perfluorooctane 
sulfonate and uric acid among 54,951 adult community 
residents in Ohio and West Virginia, who lived or worked 
in six water districts contaminated with perfluorooctanoic 
acid from a chemical plant, Steenland et al15 reported that 
the risk of hyperuricemia risk increased modestly with 
increasing perfluorooctanoic acid; the OR by quintile of 
perfluorooctanoic acid reported in that study were 1.00, 1.33 
(95% CI, 1.24–1.43), 1.35 (95% CI, 1.26–1.45), 1.47 (95% 
CI, 1.37–1.58), and 1.47 (95% CI, 1.37–1.58; test for trend, 
P , 0.0001). However, all of these studies were based on 
samples of individuals exposed to perfluorooctanoic acid 
levels that are much higher than the background exposure 
levels in the US general population.
Exposure levels of perfluoroalkyl chemicals are impor-
tant, because a recent study showed that the half-life of 
perfluorooctanoic acid was 2.9 years at higher exposure 
levels and 8.5 years at lower exposure levels, suggesting a 
concentration-dependent clearance of these chemicals from 
the human body.16 These half-life values are higher than 
those reported in previous studies examining occupational 
workers.23,24 Therefore, there is a need to examine the putative 
association between serum perfluoroalkyl chemical levels 
and uric acid at these lower levels also. It is in this context 
that the results of our study employing the nationally repre-
sentative NHANES survey are relevant. We found that both 
serum perfluorooctanoic acid and perfluorooctane sulfonate 
levels are positively associated with uric acid at low exposure 
levels seen in the US general population, even after adjusting 
for a variety of confounders.
The biological mechanisms underlying this observed 
positive association between serum uric acid and perfluo-
roalkyl chemical levels are not clear. Recent studies have 
reported that perfluorooctanoic acid exposure may be 




Unadjusted mean  
change in uric acid,  
mg/dL (95% CI)
Multivariate-adjusted  
mean change in uric 
acid, mg/dL (95% CI)‡
Sample 
size
Unadjusted mean  
change in uric acid,  
mg/dL (95% CI)
Multivariate-
adjusted mean  
change in uric acid, 
mg/dL (95% CI)‡
PFOA*
  Quartile 1 463 1 (referent) 1 (referent) 521 1 (referent) 1 (referent)
  Quartile 2 455 0.14 (-0.03, 0.30) 0.08 (-0.06, 0.22) 476 0.16 (0.01, 0.31) 0.14 (-0.03, 0.30)
  Quartile 3 471 0.39 (0.18, 0.61) 0.33 (0.15, 0.51) 532 0.37 (0.20, 0.54) 0.29 (0.15, 0.43)
  Quartile 4 468 0.48 (0.32, 0.64) 0.41 (0.24, 0.57) 497 0.50 (0.32, 0.69) 0.33 (0.12, 0.54)
 P  trend ,0.0001 ,0.0001 ,0.0001 0.0012
Log-transformed PFOA 1857 0.25 (0.13, 0.37) 0.21 (0.09, 0.34) 2026 0.27 (0.18, 0.35) 0.16 (0.06, 0.26)
PFOS†
  Quartile 1 466 1 (referent) 1 (referent) 501 1 (referent) 1 (referent)
  Quartile 2 460 0.28 (0.06, 0.50) 0.20 (-0.02, 0.43) 509 0.07 (-0.15, 0.29) 0.13 (-0.05, 0.32)
  Quartile 3 470 0.26 (0.04, 0.48) 0.20 (-0.01, 0.41) 508 0.32 (0.10, 0.55) 0.19 (-0.04, 0.41)
  Quartile 4 461 0.28 (0.06, 0.49) 0.23 (0.02, 0.44) 508 0.42 (0.16, 0.69) 0.23 (-0.02, 0.48)
 P  trend 0.0223 0.0499 0.0006 0.0706
Log-trasnformed PFOS 0.16 (0.06, 0.26) 0.11 (0.00, 0.22) 0.24 (0.09, 0.39) 0.13 (-0.01, 0.27)
Notes: *Plasma PFOA quartiles: quartile 1 (,2.4 ppb), quartile 2 (2.4–3.4 ppb), quartile 3 (3.5–5.1 ppb), quartile 4 (.5.1 ppb); in men: quartile 1 (,3.2 ppb), quartile 2 
(3.2–4.5 ppb), quartile 3 (4.6–6.4 ppb), quartile 4 (.6.4 ppb); †plasma PFOS quartiles: quartile 1 (,11.2 ppb), quartile 2 (11.2–17.8 ppb), quartile 3 (17.9–27.9 ppb), quartile 4 
(.27.9 ppb); in men: quartile 1 (,17.5 ppb), quartile 2 (17.5–24.7 ppb), quartile 3 (24.8–35.6 ppb), quartile 4 (.35.6 ppb); ‡adjusted for age (years), gender (men, women), 
race-ethnicity (non-hispanic whites, non-hispanic blacks, Mexican Americans, others), education categories (,high school, high school, .high school), smoking (never, 
former, current), alcohol intake (heavy drinker), body mass index (kg/m2), hypertension (absent, present), diabetes (absent, present), and serum total cholesterol (mg/dL). 
Abbreviations: CI, confidence interval; PFOA, perfluorooctanoic acid; PFOS, perfluorooctane sulfonate.
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related to oxidative stress in liver25,26 and endothelial cells. 
Similarly, elevations in serum uric acid may be an indirect 
measure of oxidative stress.27 Another possibility is that 
organic anion transporters 1 and 3, which are involved in the 
tubular secretion of uric acid,28 have been reported to have 
a high affinity for perfluorooctanoic acid.29 Therefore, it is 
possible that perfluorooctanoic acid may compete with the 
excretion of uric acid.
The main strengths of our study include its population-
based nature, inclusion of a representative multiethnic sample, 
Table 4 Association between plasma PFOA level and uric acid levels according to body mass index categories
Quartile BMI , 30 kg/m2 BMI $ 30 kg/m2
Sample  
size
Unadjusted mean  
change in uric acid,  
mg/dL (95% CI)
Multivariate- 
adjusted mean  




Unadjusted mean  
change in uric acid,  
mg/dL (95% CI)
Multivariate- 
adjusted mean  
change in uric acid,   
mg/dL (95% CI)‡
PFOA*
  Quartile 1 653 1 (referent) 1 (referent) 331 1 (referent) 1 (referent)
  Quartile 2 597 0.17 (0.01, 0.33) 0.16 (0.04, 0.27) 334 0.24 (-0.02, 0.49) 0.11 (-0.11, 0.32)
  Quartile 3 665 0.37 (0.19, 0.54) 0.33 (0.20, 0.46) 338 0.52 (0.25, 0.79) 0.46 (0.22, 0.70)
  Quartile 4 635 0.52 (0.35, 0.68) 0.40 (0.26, 0.55) 330 0.65 (0.34, 0.96) 0.49 (0.25, 0.73)
 P  trend ,0.0001 ,0.0001 ,0.0001 ,0.0001
Log-transformed PFOA 2550 0.45 (0.36, 0.55) 0.21 (0.13, 0.30) 1333 0.46 (0.26, 0.66) 0.23 (0.05, 0.41)
PFOS†
  Quartile 1 624 1 (referent) 1 (referent) 343 1 (referent) 1 (referent)
  Quartile 2 653 0.12 (-0.10, 0.34) 0.22 (0.06, 0.38) 316 0.22 (-0.01, 0.44) 0.11 (-0.08, 0.30)
  Quartile 3 652 0.22 (0.06, 0.38) 0.16 (-0.02, 0.34) 326 0.40 (0.05, 0.75) 0.34 (0.01, 0.67)
  Quartile 4 621 0.31 (0.12, 0.50) 0.34 (0.18, 0.50) 348 0.28 (-0.06, 0.61) 0.13 (-0.18, 0.44)
 P  trend 0.0015 0.0005 0.0600 0.2348
Log-transformed PFOS 0.42 (0.35, 0.48) 0.16 (0.08, 0.24) 0.39 (0.18, 0.59) 0.10 (-0.11, 0.30)
Notes: *Plasma PFOA quartiles: quartile 1 (,2.4 ppb), quartile 2 (2.4–3.4 ppb), quartile 3 (3.5–5.1 ppb), quartile 4 (.5.1 ppb); in men: quartile 1 (,3.2 ppb), quartile 2 
(3.2–4.5 ppb), quartile 3 (4.6–6.4 ppb), quartile 4 (.6.4 ppb); †plasma PFOS quartiles: quartile 1 (,11.2 ppb), quartile 2 (11.2–17.8 ppb), quartile 3 (17.9–27.9 ppb), quartile 4 
(.27.9 ppb); in men: quartile 1 (,17.5 ppb), quartile 2 (17.5–24.7 ppb), quartile 3 (24.8–35.6 ppb), quartile 4 (.35.6 ppb); ‡adjusted for age (years), gender (men, women), 
race-ethnicity (non-hispanic whites, non-hispanic blacks, Mexican Americans, others), education categories (,high school, high school, .high school), smoking (never, 
former, current), alcohol intake (heavy drinker), body mass index (kg/m2), hypertension (absent, present), diabetes (absent, present), and serum total cholesterol (mg/dL). 
Abbreviations: BMI, body mass index; CI, confidence interval; PFOA, perfluorooctanoic acid; PFOS, perfluorooctane sulfonate.
Table 5 Association between plasma PFOA level and hyperuricemia










  Quartile 1 984 (13.6) 1 (referent) 1 (referent) 1 (referent)
  Quartile 2 931 (15.7) 1.18 (0.82, 1.69) 1.17 (0.81, 1.69) 1.14 (0.78, 1.67)
  Quartile 3 1003 (22.0) 1.79 (1.27, 2.51) 1.84 (1.33, 2.55) 1.90 (1.35, 2.69)
  Quartile 4 965 (23.7) 1.97 (1.50, 2.59) 1.97 (1.48, 2.62) 1.97 (1.44, 2.70)
 P  trend ,0.0001 ,0.0001 ,0.0001
Log-transformed PFOA 1.62 (1.35, 1.93) 1.42 (1.19, 1.71) 1.43 (1.16, 1.76)
PFOS†
  Quartile 1 967 (14.8) 1 (referent) 1 (referent) 1 (referent)
  Quartile 2 969 (18.9) 1.34 (1.00, 1.81) 1.38 (1.02, 1.87) 1.46 (1.11, 1.91)
  Quartile 3 978 (22.6) 1.68 (1.20, 2.34) 1.63 (1.15, 2.32) 1.69 (1.19, 2.40)
  Quartile 4 969 (20.8) 1.51 (1.01, 2.24) 1.42 (0.94, 2.16) 1.48 (0.99, 2.22)
 P  trend 0.0180 0.0611 0.0433
Log-transformed PFOS 1.47 (1.20, 1.79) 1.21 (0.98, 1.50) 1.21 (0.97, 1.51)
Notes: *Plasma PFOA quartiles: quartile 1 (,2.4 ppb), quartile 2 (2.4–3.4 ppb), quartile 3 (3.5–5.1 ppb), quartile 4 (.5.1 ppb); in men: quartile 1 (,3.2 ppb), quartile 2 
(3.2–4.5 ppb), quartile 3 (4.6–6.4 ppb), quartile 4 (.6.4 ppb); †plasma PFOS quartiles: quartile 1 (,11.2 ppb), quartile 2 (11.2–17.8 ppb), quartile 3 (17.9–27.9 ppb), quartile 4 
(.27.9 ppb); in men: quartile 1 (,17.5 ppb), quartile 2 (17.5–24.7 ppb), quartile 3 (24.8–35.6 ppb), quartile 4 (.35.6 ppb); ‡adjusted for age (years), gender (men, women), 
race-ethnicity (non-hispanic whites, non-hispanic blacks, Mexican Americans, others), education categories (,high school, high school, .high school), smoking (never, 
former, current), alcohol intake (heavy drinker), body mass index (kg/m2), hypertension (absent, present), diabetes (absent, present), and serum total cholesterol (mg/dL). 
Abbreviations: CI, confidence interval; OR, odds ratio; PFOA, perfluorooctanoic acid; PFOS, perfluorooctane sulfonate; PFC, perfluoroalkyl chemicals.
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adequate sample size, objective measurement of diabetes 
status following current guidelines, and the availability of 
extensive data on confounders for multivariate adjustment. 
The main limitation of our study is the cross-sectional 
nature of NHANES. Therefore, similar to previous studies 
that examined the association between other environmental 
exposures and disease states using the NHANES data, the 
temporal nature of the association between perfluoroalkyl 
chemicals and diabetes cannot be concluded from the current 
study. Another limitation is that adjustment for variables 
that are potential mediators, such as hypertension in the 
multivariate model, may be an overadjustment, and therefore 
may have led to an underestimation of the true association 
between serum perfluoroalkyl chemical levels and uric 
acid. It is possible that the true association may be in fact of 
stronger magnitude.
In summary, we found that serum perfluoroalkyl 
chemical levels were positively associated with elevated 
uric acid in a representative, multiethnic sample of US 
adults. This association was found to be independent of 
age, gender, race-ethnicity, education, smoking, alcohol 
intake, body mass index, hypertension, diabetes, and serum 
total cholesterol. Our results contribute to the literature by 
suggesting that perfluoroalkyl chemical levels are related 
to uric acid, even at low exposure levels, in the general 
population.
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